Warren, NJ and Portage, Ind. (June 5, 2008) – MonoSol Rx, a drug delivery company specializing in dissolving thin film pharmaceutical products, announced today the appointment of Vincent Viviani as Senior Vice President, Manufacturing and Operations. Mr. Viviani will report to A. Mark Schobel, President and CEO and join the Company’s executive management team.
Mr. Schobel commented, “Vince is a significant addition to the MonoSol Rx executive team. His leadership and experience will be instrumental as we look to further enhance the productivity and operational efficiency of our recently expanded manufacturing facilities. Since bringing our second manufacturing facility online, we have tripled our production capacity to more than three billion strips annually. This additional capacity will help us to meet the growing demand for our thin film drug delivery technology in both the consumer and prescription drug markets.”
Mr. Viviani joins MonoSol Rx after leading his own consulting firm from 2006 to 2008. As President of Viviani Consulting, Mr. Viviani specialized in helping small and medium-sized businesses develop strategies to bolster profitability, operational functionality and business process management. Prior to his consulting work, Mr. Viviani was Vice President, Quality Systems for Playtex Products, Inc. where he developed and led corporate-wide quality systems. Earlier in his career, Mr. Viviani held various manufacturing and operations positions with Reckitt & Colman and was Director of Distribution and Logistics for Lechters, Inc.
About MonoSol Rx
MonoSol Rx is a drug delivery company specializing in proprietary, dissolving thin film pharmaceutical products. The Company’s thin film technology, which is similar in size, shape and thickness to a postage stamp, dissolves rapidly and utilizes a novel process and proprietary encapsulation compositions to mask the taste of the drug contained within the film. MonoSol Rx’s strategy is to develop and partner innovative thin film strip products in the prescription, generic and OTC pharmaceutical markets and to establish a leadership position in thin film drug delivery technology through continued development of its drug delivery technology and intellectual property portfolio.